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Abstract
Background
Optimising the use of antibiotics is a key component of antibiotic stewardship. Respiratory
tract infections (RTIs) are the most common reason for antibiotic prescription in children,
even though most of these infections in children under 5 years are viral. This study aims to
safely reduce antibiotic prescriptions in children under 5 years with suspected lower RTI at
the emergency department (ED), by implementing a clinical decision rule.
Methods and findings
In a stepped-wedge cluster randomised trial, we included children aged 1–60 months pre-
senting with fever and cough or dyspnoea to 8 EDs in The Netherlands. The EDs were of
varying sizes, from diverse geographic and demographic regions, and of different hospital
types (tertiary versus general). In the pre-intervention phase, children received usual care,
according to the Dutch and NICE guidelines for febrile children. During the intervention
phase, a validated clinical prediction model (Feverkidstool) including clinical characteristics
and C-reactive protein (CRP) was implemented as a decision rule guiding antibiotic pre-
scription. The intervention was that antibiotics were withheld in children with a low or inter-
mediate predicted risk of bacterial pneumonia (�10%, based on Feverkidstool). Co-primary
outcomes were antibiotic prescription rate and strategy failure. Strategy failure was defined
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Data Availability Statement: Individual participant
data that underlie the results reported in this article
as secondary antibiotic prescriptions or hospitalisations, persistence of fever or oxygen
dependency up to day 7, or complications. Hospitals were randomly allocated to 1 sequence
of treatment each, using computer randomisation. The trial could not be blinded. We used
multilevel logistic regression to estimate the effect of the intervention, clustered by hospital
and adjusted for time period, age, sex, season, ill appearance, and fever duration; predicted
risk was included in exploratory analysis. We included 999 children (61% male, median age
17 months [IQR 9 to 30]) between 1 January 2016 and 30 September 2018: 597 during the
pre-intervention phase and 402 during the intervention phase. Most children (77%) were
referred by a general practitioner, and half of children were hospitalised. Intention-to-treat
analyses showed that overall antibiotic prescription was not reduced (30% to 25%, adjusted
odds ratio [aOR] 1.07 [95% CI 0.57 to 2.01, p = 0.75]); strategy failure reduced from 23% to
16% (aOR 0.53 [95% CI 0.32 to 0.88, p = 0.01]). Exploratory analyses showed that the inter-
vention influenced risk groups differently (p < 0.01), resulting in a reduction in antibiotic pre-
scriptions in low/intermediate-risk children (17% to 6%; aOR 0.31 [95% CI 0.12 to 0.81, p =
0.02]) and a non-significant increase in the high-risk group (47% to 59%; aOR 2.28 [95% CI
0.84 to 6.17, p = 0.09]). Two complications occurred during the trial: 1 admission to the
intensive care unit during follow-up and 1 pleural empyema at day 10 (both unrelated to the
study intervention). Main limitations of the study were missing CRP values in the pre-inter-
vention phase and a prolonged baseline period due to logistical issues, potentially affecting
the power of our study.
Conclusions
In this multicentre ED study, we observed that a clinical decision rule for childhood pneumo-
nia did not reduce overall antibiotic prescription, but that it was non-inferior to usual care.
Exploratory analyses showed fewer strategy failures and that fewer antibiotics were pre-
scribed in low/intermediate-risk children, suggesting improved targeting of antibiotics by the
decision rule.
Trial registration
Netherlands Trial Register NTR5326.
Author summary
Why was this study done?
• Symptoms of lower respiratory tract infections (RTIs) are very common in children,
and the most common reason for children to receive antibiotics in the emergency
department (ED).
• A large number of these antibiotic prescriptions may be unnecessary, because most
respiratory infections in children are caused by viruses, which are not susceptible to
antibiotic treatment.
A decision rule guiding antibiotics in children with suspected lower RTIs
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• Currently, there is no good test to determine whether an infection is caused by a virus
or by bacteria, resulting in over-prescription of antibiotics, which in turn can lead to
side effects and antibiotic resistance.
What did the researchers do and find?
• We introduced a clinical decision rule for children with suspected lower RTI in the ED,
advising doctors about the child’s risk of having a bacterial infection (based on their
symptoms), so that they would not prescribe antibiotics to children who had a low or
intermediate risk.
• We found that this decision rule did not reduce antibiotic prescriptions when we looked
at all children, but that it was safe to use the rule.
• It seemed that, with this decision rule, a higher number of children responded well to
their initial treatment (for example, fewer children needed antibiotics in the week after
the ED visit, and more children recovered quickly) and that the antibiotic prescriptions
shifted from children at low/intermediate risk towards children at high risk of bacterial
infection.
What do these findings mean?
• We observed that it was safe to use the decision rule for guiding antibiotic treatment in
children with a suspected lower RTI in the ED.
• It also seemed that, with the decision rule, antibiotics were more often prescribed to
children who actually needed them, leading to better recovery from the disease.
• Limitations of our study were that it took more time than expected to organise the logis-
tics of the trial before introduction of the decision rule, and that not all children received
a C-reactive protein blood test in the usual care (control) period of the trial, which may
have influenced the power of the study.
Introduction
Respiratory tract infections (RTIs) are the most common diagnosis in febrile children, and the
most common reason for antibiotic prescription in children [1]. In children under 5 years,
most lower RTIs are viral [2]. Although mortality caused by lower RTIs has decreased signifi-
cantly over the past decades (currently 1.7 per 100,000 people in Western Europe) [3], antimi-
crobial resistance due to unnecessary antibiotic prescription is increasing [4]. High variability
in antibiotic prescription in children with RTIs in primary as well as hospital care throughout
Europe highlights the need for better targeting of antibiotic prescriptions in this patient group
[1,5,6].
One of the main challenges when attempting to safely reduce antibiotic prescriptions for
lower RTIs in children is the absence of a gold standard for the diagnosis of bacterial pneumo-
nia. Routine chest X-rays are no longer recommended for the differentiation between bacterial
and viral causes, and treatment decisions are mostly based on clinical findings [7,8]. Ongoing
A decision rule guiding antibiotics in children with suspected lower RTIs
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research into new biomarkers has not yet provided a new gold standard for clinical practice in
the emergency department (ED) [9–11]. In the absence of a gold standard for diagnosing bac-
terial pneumonia, we need to improve the clinical detection rate of those children who may
benefit most from antibiotic treatment of bacterial pneumonia. Clinical prediction models
combining clinical characteristics and biomarkers may improve the identification of children
who will benefit from antibiotic treatment for community-acquired pneumonia, but they are
not used as decision rules in clinical practice [12,13]. The Feverkidstool is a clinical prediction
model combining clinical characteristics and C-reactive protein (CRP) to predict the risk of
bacterial pneumonia and other serious bacterial infections in children. The model was derived
in the ED setting in The Netherlands, and its diagnostic accuracy has been proven in external
validation studies in The Netherlands and the United Kingdom [13,14].
In this study we evaluated the impact of the Feverkidstool on clinical practice, as a last step
in the development of a prediction model [15]. We translated the Feverkidstool into a decision
rule with pre-specified decision thresholds to guide antibiotic treatment for lower RTIs. The
primary objective of this study was to safely reduce antibiotic prescription in children under 5
years with suspected lower RTI at the ED, by withholding antibiotics in children at low or
intermediate risk of bacterial pneumonia, as predicted by the Feverkidstool.
Methods
Study design
We performed a stepped-wedge cluster randomised trial with sequential implementation of a
treatment strategy for antibiotic prescription based on a clinical decision rule (hereafter called
‘decision rule’) in febrile children with suspected lower RTI in the ED. Randomisation at clus-
ter level was chosen to avoid contamination of the intervention effect to control patients. The
stepped-wedge design was preferred as, in general, smaller sample sizes are needed than in
conventional cluster randomised trials. Because clusters act as their own controls, the interven-
tion effect can be estimated from both between and within cluster comparisons. The sequential
implementation of the intervention was deemed superior to a conventional before–after
design, given the incorporation of time effects [16]. We performed the trial in 8 clusters (hospi-
tals) between 1 January 2016 and 30 September 2018 in The Netherlands. By design, the trial
consisted of 2 phases: a pre-intervention phase, when usual care was provided, and an inter-
vention phase, wherein care was provided according to our intervention (diagram of trial
design in Fig 1). A cluster consisted of 1 hospital that was randomised to 1 sequence of treat-
ment. Each hospital was randomised to 1 sequence of treatment, resulting in 8 sequences. The
period when all hospitals still performed usual care (the baseline period) was followed by a roll-
out period, during which the hospitals switched sequentially to the intervention (antibiotic
prescription guided by the decision rule). At intervals of 4 weeks, hospitals were randomised
to start the intervention between 28 August 2017 and 12 March 2018. This timing was chosen
to take the seasonality of RTIs into account, as most eligible patients were expected during
autumn and winter. Given the short duration of illness, the patients included in the different
time periods were different people. The original and the final study protocol are available as S1
Text and S2 Text. The trial was approved by the ethics committee of Erasmus MC (MEC-
2014-332) and by the participating hospitals. Written informed consent was obtained from the
parents of all participants by the treating physician, in both phases of the trial. In the pre-inter-
vention phase, this consent concerned the use of clinical data and performance of follow-up;
in the intervention phase, it also concerned the use of the Feverkidstool to guide treatment
decisions. Consent was obtained before calculating the predicted risk of the child. The trial
was registered in the Netherlands Trial Register (NTR) (NTR5326). As reported in the NTR, 1
A decision rule guiding antibiotics in children with suspected lower RTIs
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cluster was added during the pre-intervention period, to ensure sufficient inclusions. Interim
analysis after the first year of data collection (but before implementation of the intervention)
showed substantially higher antibiotic prescription rates than anticipated. Based on the distri-
bution of risks and actual antibiotic prescription rates during the pre-intervention period, the
target sample size was adjusted from 1,100 to 900 children, which is also reported in the NTR.
No other important methodological changes were made after the start of the trial. The study
was reported according to the CONSORT guideline for clinical trials and the extension for
stepped-wedge cluster randomised trials (S1 Table).
Participants
We included children aged 1–60 months that presented with fever (reported by parents or
measured as>38.5˚ C at the ED) and cough or dyspnoea as symptoms of potential lower RTI
at the EDs of 8 hospitals in The Netherlands. This target population included children with all
different risk profiles, since at presentation in the ED their risk profile was unknown. We
excluded children at increased risk of a complicated course: children with relevant comorbidi-
ties, antibiotic use in the week prior to ED visit, amoxicillin allergies, another identifiable
infectious focus (cutaneous, otitis media, tonsillitis), or signs of complicated pneumonia at
Fig 1. Design of the trial. ED, emergency department.
https://doi.org/10.1371/journal.pmed.1003034.g001
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presentation (oxygen saturation < 85%, respiratory insufficiency, empyema, sepsis). Relevant
comorbidities were immunodeficiency, congenital heart defect, chronic pulmonary disease,
multiple handicaps, and prematurity (born before the gestational age of 32 weeks and aged<1
year at time of presentation). Individual participants were included in the clusters by continu-
ous recruitment by the treating physician in the ED. We included 8 hospitals in 6 cities of the
southwest and central area of The Netherlands (a) where paediatricians were responsible for
the children presenting at the ED, (b) with varying ED sizes (range 500–13,000 annual paediat-
ric ED admissions), (c) from diverse geographic and demographic regions (inner-city and
mixed rural/urban), and (d) of different hospital types (tertiary and general). Hospitals were
separated geographically, with no exchange of staff. The hospitals were recruited by the princi-
pal investigator (RO).
Randomisation and blinding
Randomisation of sequences of treatment was performed in July 2017 (after recruitment of all
8 clusters) by a statistician using computer randomisation. The statistician was involved as an
advisor in the trial and was based at Erasmus MC. He knew the names of the other participat-
ing centres at randomisation, but had no further knowledge of these hospitals or relation to
the local researchers. Since 2 hospitals started in August 2017 with the pre-intervention phase
due to logistical reasons, these hospitals were randomised to start the intervention after time
period 3 (Fig 1). This was accounted for in the original randomisation prior to the rollout
period. The trial could not be blinded, because the intervention was the implementation and
use of a decision rule by clinicians in the ED, including treatment advice based on the risk
score that had to be calculated for each child.
Intervention
During the pre-intervention phase, all children received usual care. Usual care consisted of tri-
age by a nurse, including the routine measurement of vital signs, followed by a clinical assess-
ment and initiation of therapy by a physician, according to the Dutch and NICE guidelines for
febrile children [17,18]. Additional diagnostics were performed at the discretion of the treating
physician. CRP testing was often done as part of usual care, but without specific thresholds for
decision-making. Other blood tests or chest X-rays were not routinely performed in children
with suspected lower RTI, in line with the Dutch guideline, which is based on the British Tho-
racic Society guideline for the management of children with community-acquired pneumonia
[8]. During usual care, antibiotics were prescribed at the discretion of the treating physician.
Amoxicillin was usually prescribed as first-line treatment for community-acquired pneumonia
[8].
During the intervention phase, a validated clinical prediction model (Feverkidstool) was
implemented as a decision rule guiding antibiotic prescription at the cluster level [12,13]. We
predefined decision thresholds that would guide antibiotic treatment decisions, balancing pos-
itive and negative likelihood ratios and the consequences of over- and undertreatment [12,19].
The intervention was a decision-rule-based treatment strategy for all children with suspected
lower RTI in the ED, with a differential effect on risk groups. In children with a low (�3%) or
intermediate (4%–10%) predicted risk of bacterial pneumonia, antibiotics were withheld. In
children with a high predicted risk (>10%), usual care was provided, i.e., antibiotics were pre-
scribed at the discretion of the physician. The Feverkidstool included the following predictors:
age in years, sex, duration of fever in days, ill appearance (yes/no), chest wall retractions (yes/
no), capillary refill time in seconds, hypoxia (oxygen saturation < 94%), tachypnoea (based on
Advanced Paediatric Life Support guideline), tachycardia (idem), temperature in degrees
A decision rule guiding antibiotics in children with suspected lower RTIs
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Celsius, and CRP in mg/l. Ill appearance was based on the judgment of the treating clinician.
Although ill appearance was not defined by specific criteria, in the development and validation
of the Feverkidstool this characteristic appeared to be valid and consistent among different
populations [12]. More details about the development of the Feverkidstool have been pub-
lished previously [12]. The tool was available to all treating physicians as an online digital cal-
culator. The individual predicted risk was calculated after the physician’s clinical assessment of
the child and CRP testing, but before the treatment decision was made. During both phases of
the study, a structured follow-up via telephone was performed 7 days after the ED visit. During
the intervention phase, children with an intermediate or high predicted risk received an extra
follow-up call 2 days after the ED visit to timely identify potential deterioration of the patient.
When children were still hospitalised at those time points, the follow-up information was col-
lected directly from the parents and the patient’s electronic health record.
Outcomes
Primary outcomes were antibiotic prescription at ED discharge (yes/no) and strategy failure
within 7 days after the initial ED visit (yes/no). Since the decision rule should not impact
patient outcomes negatively (complying with our aim ‘to safely reduce antibiotic prescrip-
tions’), we viewed antibiotic prescription and strategy failure as equally important co-primary
outcomes. Strategy failure was a composite outcome, based on the follow-up on day 7 and
defined as secondary hospitalisation (i.e., hospitalisation during follow-up, after the initial dis-
charge), secondary or switched antibiotic prescription (during follow-up), oxygen dependency
or fever up to day 7, or the development of complications. Since there is no single and objective
measure of failure of antibiotic treatment strategy, we used this predefined composite outcome
for strategy failure. This outcome was chosen to cover different aspects of strategy failure that
are important in clinical practice and may be related to the initial treatment strategy at the ED
[20]. It includes changes in the treatment strategy for the child (secondary or switched antibi-
otic treatment and secondary hospitalisation) as well as signs of prolonged or complicated dis-
ease (oxygen dependency or fever up to day 7 and complications). Changes in treatment
strategy during follow-up were made without specific recommendations in the study protocol.
Reasons for switching antibiotic prescription were not systematically recorded. Switching of
antibiotics due to adverse drug reaction was considered a strategy failure. We used a short fol-
low-up period of 1 week, assuming that a secondary hospitalisation within this time frame was
related to the respiratory illness. All secondary prescriptions and secondary hospitalisations
were considered a strategy failure. Secondary outcomes were the level of compliance to the
intervention and the number of complications. Compliance was defined as the number of chil-
dren in whom the Feverkidstool was calculated and who were treated according to the decision
rule out of the total number of children included during the intervention phase. Complications
were defined as the presence of pleural empyema, parapneumonic effusion (any size), pulmo-
nary abscess, or respiratory insufficiency (need for mechanical ventilation) by day 7. No
changes were made to the outcomes after the trial commenced.
Statistical methods
Sample size. We calculated the needed sample size for the 2 co-primary outcomes based
on methods by Hussey and Hughes, without accounting for multiple testing [16]. We based
our sample size calculation on the complete target population of children with suspected lower
RTI in the ED, including all risk groups. Based on previous studies [14], we assumed that 50%
of the population would be at low risk, 30% at intermediate risk, and 20% at high risk, with
antibiotic prescription rates of 35% (in the low-risk group), 40% (intermediate-risk group),
A decision rule guiding antibiotics in children with suspected lower RTIs
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and 85% (high-risk group). The decision rule was expected to affect risk groups differently: we
estimated no difference in antibiotic prescription in the high-risk patients, and a reduction of
10–15 percentage points in the low-risk and intermediate-risk patients, leading to an overall
reduction of antibiotic prescriptions of 10 percentage points. The intracluster correlation coef-
ficient (ICC) was unknown, but we assumed that a power of 90% at independency (i.e., no cor-
relation between clusters, ICC of 0) would result in a power of 80% or more in multilevel
analysis. We assumed different cluster sizes (small, intermediate, and large clusters) and
3-level seasonal variation in inclusion of patients. All assumptions are listed in S3 Text. Based
on these assumptions, we originally estimated a needed sample size of 1,100 children with a
suspected lower RTI. Interim analysis of inclusions during the first year showed a higher base-
line prescription rate than was assumed. An interim power calculation based on this rate
resulted in a needed sample size of 900 children to show superiority of the decision rule for
antibiotic prescription with a power of 0.9 and an alpha of 0.05 (see S1 Text). This number was
also sensitive to show non-inferiority of the intervention in terms of strategy failure with a
non-inferiority margin of 5%: It could detect a 2-fold increase of secondary hospitalisation
(the part of strategy failure with available baseline data: 5% at the time of original sample size
calculation) with a power of 0.8 and alpha of 0.05. The interim power analysis was performed
before introduction of the intervention, so it was blinded to the outcomes of the trial [21].
Primary analyses. We used multilevel generalised linear mixed models to calculate the
impact of the intervention on our 2 primary outcomes: antibiotic prescription and strategy
failure. Hospitals were added as a random effect to take clustering at the hospital level into
account. Time period (1–9) was added as a fixed effect to adjust for a secular time trend intro-
duced by the design of the study [22]. In the primary analyses we adjusted for pre-specified fac-
tors that may have influenced participation in the study or compliance to the protocol, i.e.,
age, sex, fever duration, season, and ill appearance. We tested the linearity of the associations
between continuous predictors and outcomes. Detailed models can be found in the pre-speci-
fied statistical analysis plan (S4 Text). We performed an intention-to-treat analysis, i.e., the
intervention population contained all of the children in the intervention phase, including
those cases where doctors did not comply to the protocol (Fig 2). We analysed the outcome
strategy failure in all children with follow-up information on strategy failure available. We also
performed per-protocol analyses to evaluate the impact of the decision rule on the primary
outcomes in cases of compliance to the protocol. For this per-protocol analysis, the interven-
tion group consisted only of those children in whom the physicians complied to the protocol
(Fig 2).
Secondary analyses. We report the level of compliance to the intervention and the num-
ber of complications during both phases of the study.
Pre-specified sensitivity analyses. We pre-specified 4 sensitivity analyses. First, to esti-
mate the effect of the imputation of missing covariates on our primary analyses, we planned a
sensitivity analysis on all covariates with>10% missing values, using different assumptions.
Second, to evaluate the effect of loss to follow-up on the outcome strategy failure, we planned a
sensitivity analysis assuming that (a) strategy failure occurred in all children with missing fol-
low-up or (b) strategy failure occurred in none of those children. Third, to evaluate the effect
of the longer baseline and post-rollout periods, we performed a sensitivity analysis of the pri-
mary outcome that only used data from 4 weeks before until 4 weeks after the rollout period
(31 July 2017–8 April 2018), resulting in 9 time periods of equal length. Fourth, the level of
routine measurement of CRP in the pre-intervention phase differed between hospitals. To
adjust for this factor, we performed a sensitivity analysis on the data of only those hospitals
that did perform routine CRP measurement in the population throughout both phases of the
study.
A decision rule guiding antibiotics in children with suspected lower RTIs
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003034 January 31, 2020 8 / 19
Exploratory subgroup analysis. We performed an exploratory subgroup analysis of the
primary outcomes in the different risk groups. Because our intervention was to withhold anti-
biotics in children at low or intermediate risk of bacterial pneumonia, we expected the most
Fig 2. Flowchart of inclusion. CRF, case report form; ED, emergency department.
https://doi.org/10.1371/journal.pmed.1003034.g002
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effect on primary outcomes in those risk groups. However, our study was not powered for sub-
group analyses, so we performed these post hoc as exploratory analyses, to generate hypotheses
for the interpretation of the overall primary results. We analysed the primary outcomes in the
low- and intermediate-risk groups combined (�10%) versus the high predicted risk (>10%)
group, testing for a difference in effect using an interaction term (intervention × risk group).
For these analyses we used the data of all children in whom the Feverkidstool—and thereby
the risk group—could be calculated (complete case analysis), because we could not select sub-
groups based on imputed data. We did not perform other post hoc analyses.
Missing data. We assumed missing data to be missing at random, and handled missing
covariates by means of multiple imputation using the mice package in R (version 3.3.4). The
imputation model included all of the variables needed for the primary and sensitivity analyses,
as well as additional information on diagnosis, treatment, disposition, and follow-up. Outcome
variables (antibiotic prescription and strategy failure) were not imputed, except for the sensi-
tivity analysis evaluating the effect of loss to follow-up on the outcome strategy failure. In this
sensitivity analysis we used single imputation only for the outcome variable strategy failure,
assuming 100% failure if the variable was missing in one dataset versus 0% failure in another
dataset. We did not impute predicted risk for the selection of risk groups in the exploratory
analyses. If parents could not be reached for a follow-up on day 7 via telephone, follow-up
information was retrieved from the child’s electronic health record.
Results
Recruitment
The baseline period ran from 1 January 2016 to 27 August 2017, and from 28 August 2017 to
12 March 2018 (the rollout period) the hospitals started the intervention phase one by one
every 4 weeks; we collected data until 30 September 2018, when the target sample size was
reached (Fig 1). All hospitals adhered to their allocated sequence of treatment and the planned
rollout dates. All hospitals that were assessed for eligibility were recruited (n = 8); after recruit-
ment, all 8 were randomised to a treatment sequence and included in the analyses (Fig 1). In
total, 1,704 children were assessed for eligibility, and 1,027 children included in the trial (375
not included in the pre-intervention phase, 302 in the intervention phase). Of the included
children, 28 children met the exclusion criteria, leaving 999 children for analyses of the pri-
mary outcome antibiotic prescription. Of these, 46 (5%) were lost to follow-up. Because the
outcome strategy failure was based on follow-up, and because we did not impute outcome var-
iables, the remaining 953 children were included in the analyses for strategy failure. Details of
patient flow in the trial can be found in Fig 2, and details of inclusion at the cluster level in Fig
1. The main reason for non-inclusion of patients was that the ED was too busy to enrol patients
in the trial. The children not included were generally less severely ill, reflected by a lower
urgency at triage, fewer antibiotic prescriptions, and fewer hospitalisations (S2 Table).
Baseline data
The majority of children were male (n = 611, 61%), their median age was 17 months (inter-
quartile range [IQR] 9 to 30), and most were referred to the ED by a general practitioner
(Table 1). One-third of children appeared ill upon ED presentation, and the majority were
tachycardic or tachypnoeic or exhibited chest wall retractions. Half of children were hospital-
ised, for a median duration of 3 days, mainly for oxygen therapy. During the pre-intervention
phase, CRP testing was not routinely performed in all children, depending on differences in
usual care in the participating hospitals. One hospital was a tertiary care centre; the others
A decision rule guiding antibiotics in children with suspected lower RTIs
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Table 1. Baseline characteristics of the study population.
Pre-intervention
n = 597
Intervention
n = 402Characteristic
General characteristics
Male sex 364/597 (61%) 246/402 (61%)
Age in months 17 (9–30) 17 (9–31)
Season
Spring 76/597 (13%) 114/402 (28%)
Summer 55/597 (9%) 49/402 (12%)
Autumn 198/597 (33%) 88/402 (22%)
Winter 268/597 (45%) 151/402 (38%)
Way of referral to ED
General practitioner 441/578 (76%) 295/379 (78%)
Self 66/578 (11%) 45/379 (12%)
Other healthcare professional 71/578 (12%) 39/379 (10%)
Triage level
Immediate or very urgent 306/506 (60%) 182/332 (55%)
Urgent 146/506 (29%) 121/332 (36%)
Standard or non-urgent 54/506 (11%) 29/332 (9%)
Signs and symptoms
Ill appearance� 220/572 (38%) 138/400 (35%)
Duration of fever in days 2 (1–4) 2 (1–4)
Temperature in˚C 38.8 (38.1–39.5) 38.9 (38.1–39.5)
Hypoxia (oxygen saturation < 94%) 144/595 (24%) 74/401 (18%)
Tachycardia 416/595 (70%) 274/402 (68%)
Tachypnoea 487/581 (84%) 315/402 (78%)
Retractions 376/578 (65%) 237/401 (59%)
Dyspnoea 432/581 (74%) 290/402 (72%)
Wheezing 233/565 (41%) 132/395 (33%)
Prolonged capillary refill (�2 seconds) 96/553 (17%) 19/401 (5%)
Management
C-reactive protein test performed 372/597 (62%) 380/402 (95%)
C-reactive protein in mg/l 19 (7–44) 18 (7–38)
Chest X-ray performed 109/597 (18%) 49/402 (12%)
Discharge diagnosis
Pneumonia 204/594 (34%) 110/401 (27%)
Bronchiolitis 117/594 (20%) 79/401 (20%)
Upper RTI 197/594 (33%) 156/401 (39%)
Viral induced wheeze 69/594 (12%) 49/401 (12%)
Other 7/594 (1%) 7/401 (2%)
Hospitalisation 329/597 (55%) 181/402 (45%)
Length of stay in days 3 (2–5) 3 (2–5)
Reason for hospitalisation
Oxygen therapy 235/329 (71%) 132/180 (73%)
Intake of antibiotics 8/329 (2%) 2/180 (1%)
Nebuliser bronchodilator 10/329 (3%) 4/180 (2%)
Monitoring 69/329 (21%) 39/180 (22%)
Other 7/329 (2%) 3/180 (2%)
Type of antibiotic prescribed
(Continued)
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were general hospitals (see S3 Table for baseline characteristics per hospital). Annual admis-
sions to the paediatric EDs ranged from 500 to 13,000 (Fig 1).
Primary and sensitivity analyses
Overall antibiotic prescription was not reduced in the intervention phase (30% versus 25%;
adjusted odds ratio [aOR] 1.07, 95% CI 0.57 to 2.01, p = 0.75; Table 2). Antibiotic prescription
rates per hospital and per time period are provided in S4 Table. Strategy failure decreased
from 23% in the pre-intervention phase to 16% in the intervention phase (aOR 0.53, 95% CI
0.32 to 0.88, p = 0.01). The per-protocol analysis gave similar results as the intention-to-treat
analysis, showing that non-compliance to the decision rule did not influence the observed
effect on the primary outcomes. Also the results of the sensitivity analysis with truncated base-
line and post-rollout periods were comparable to the analyses on the whole population
(Table 2). Two pre-planned sensitivity analyses were not needed: adjusting for missing covari-
ates and adjusting for level of CRP measurement in pre-intervention phase. All covariates for
the primary analyses had less than 10% missing values (Table 1), so we assume that no bias was
introduced by multiple imputation. There was no difference in the level of CRP measurement
between hospitals that performed CRP routinely during the pre-intervention phase and those
that did not. Loss to follow-up had no effect on the outcome strategy failure, as shown by the
sensitivity analyses that assumed different outcomes for those lost to follow-up (Table 2). Sec-
ondary antibiotic prescription was the most frequent reason for strategy failure (Table 2).
Secondary analyses
In 43/402 (11%) cases, the clinician was not compliant with the decision rule (Table 2). Two
complications occurred during the trial: in the pre-intervention phase 1 child was admitted to
the intensive care unit during follow-up for mechanical ventilation; in the intervention phase 1
child developed pleural empyema at day 10. Both complications were unrelated to the study
intervention, since both patients treated with antibiotics at the first ED visit.
Exploratory subgroup analysis: Risk groups
We had complete information on all Feverkidstool predictors in 331/597 (55%) of the children
in the pre-intervention phase. CRP was the most frequent missing variable (225/597, 38%).
The complete case analysis showed that the effect of the decision rule was different across risk
Table 1. (Continued)
Pre-intervention
n = 597
Intervention
n = 402Characteristic
Amoxicillin 152/179 (85%) 84/101 (83%)
Amoxicillin/clavulanic acid 8/179 (4%) 6/101 (6%)
Azithromycin 17/179 (9%) 4/101 (4%)
Cefuroxime 2/179 (1%) 1/101 (1%)
Other 0/179 (0%) 5/101 (5%)
Unknown 0/179 (0%) 1/101 (1%)
Categorical variables are presented as number/total (percentage), and continuous variables as median (interquartile range). The pre-intervention and intervention
populations in a stepped-wedge trial cannot be directly compared, but should be adjusted for a secular time trend [22].
�Based on physician’s judgment (yes/no).
ED, emergency department; RTI, respiratory tract infection.
https://doi.org/10.1371/journal.pmed.1003034.t001
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groups (p< 0.01; Table 3). Antibiotic prescription was lower in the low and intermediate risk
groups combined (�10% predicted risk) during the intervention phase, whereas in the high-
risk group prescription rates were higher, but not statistically significantly so. The reduction in
strategy failure was observed in the high-risk group (Table 3), mainly via fewer secondary anti-
biotic prescriptions and less frequent fever at day 7 (S5 Table).
Table 2. Antibiotic prescription and strategy failure.
Analysis and outcome Number/total (percentage) Unadjusted Adjusted
Pre-
intervention
Intervention OR� (95% CI) p-Value† OR‡ (95% CI) p-Value†
Primary analyses
Intention-to-treat population
Antibiotic prescription 179/597 (30%) 101/402
(25%)
1.06 (0.61–
1.85)
0.84 1.07 (0.57–
2.01)
0.75
Strategy failure 131/572 (23%) 61/381 (16%) 0.56 (0.34–
0.93)
0.02 0.53 (0.32–
0.88)
0.01
Per-protocol population
Antibiotic prescription 179/597 (30%) 83/359 (23%) 0.89 (0.5–1.61) 0.71 0.96 (0.49–
1.88)
0.92
Strategy failure 131/572 (23%) 57/340 (17%) 0.60 (0.36–
1.00)
0.05 0.56 (0.34–
0.93)
0.03
Sensitivity analyses
Truncated baseline and post-rollout periods§
Antibiotic prescription 66/276 (24%) 64/279 (23%) 0.81 (0.45–
1.46)
0.48 0.71 (0.38–
1.32)
0.27
Strategy failure 58/261 (22%) 46/269 (17%) 0.57 (0.35–
0.94)
0.03 0.54 (0.33–
0.90)
0.02
Strategy failure, including missing values
Assumption missing = failure 156/597 (26%) 82/402 (20%) 0.56 (0.36–
0.88)
0.01 0.55 (0.35–
0.87)
0.01
Assumption missing = no failure 131/597 (22%) 61/402 (15%) 0.59 (0.36–
0.96)
0.03 0.56 (0.34–
0.91)
0.02
Secondary analyses
Compliance (Feverkidstool calculated and patient treated according to
advice)
NA 359/402
(89%)
Complications¶ 1/572 (0.1%) 1/381 (0.2%)
Strategy failure: reasons
Secondary antibiotic prescription 45/572 (8%) 29/381 (8%)
Changed antibiotics during follow-up 14/572 (2%) 5/381 (1%)
Secondary hospitalisation�� 16/572 (3%) 13/381 (3%)
Oxygen need at day 7 9/572 (2%) 1/381 (0.2%)
Fever at day 7 47/572 (8%) 13/381 (3%)
Bolding indicates statistical significance.
�Main model: clustered by hospital, adjusted for time period. Time-adjusted intracluster correlation coefficient for antibiotic prescription = 0.04, for strategy failure = 0.
†p-Values based on multivariable logistic regression.
‡Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.
§Using data from 4 weeks before until 4 weeks after the rollout period, resulting in 9 time periods of equal length, truncating the prolonged baseline and post-rollout
periods.
¶Complications were 1 admission to intensive care unit in the pre-intervention phase and 1 pleural empyema in the intervention phase (both unrelated to study
intervention).
��Including 1 admission to the intensive care unit in the pre-intervention group.
NA, not applicable.
https://doi.org/10.1371/journal.pmed.1003034.t002
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Discussion
We showed that a clinical decision rule did not reduce overall antibiotic prescription in chil-
dren with suspected lower RTI in the ED, but that it did reduce strategy failure. Exploratory
subgroup analyses showed that the intervention influenced the outcomes in the risk groups
differently.
Our primary aim was to safely reduce antibiotic prescription in children under 5 years with
suspected lower RTI at the ED. We hypothesized that introducing a decision rule as an inter-
vention would safely reduce antibiotic prescriptions in these children. This target population
included children with all different risk profiles, since at presentation in the ED their risk was
unknown. The first primary endpoint of reducing antibiotic prescription was not met. The
other primary endpoint of not increasing strategy failure was met. Moreover, we observed a
reduction in strategy failure, suggesting that antibiotic prescriptions were more appropriately
targeted to children who benefited from antibiotics. This additional hypothesis was supported
by our exploratory subgroup analysis, showing a safe reduction in antibiotic treatments in the
low/intermediate-risk group and a (non-significant) increase of prescriptions and a reduction
of strategy failures in the high-risk children. This suggests a shift in antibiotic prescriptions
from the low/intermediate-risk children towards the high-risk children who had more clinical
benefit from the antibiotics. Our power calculation was based on the complete target popula-
tion of children with suspected lower RTI, assuming a distribution of risk based on previous
research. Post hoc sensitivity analysis of the sample size calculation showed that our study was
sufficiently powered (power of 0.8), also when accounting for clustering at varying ICC values
(range 0.01–0.26) and adjusted for multiple testing. However, we observed a smaller propor-
tion of low/intermediate-risk children in our study population than expected. The shift in anti-
biotic prescriptions towards high-risk children and the observed smaller proportion of low/
intermediate-risk children in our study may explain why we did not detect an overall reduc-
tion in antibiotic prescription. However, it must be noted that this finding was based on com-
plete case analysis only and that our study was not powered for subgroup analyses.
We used a composite outcome to define strategy failure. Composite outcomes can be prob-
lematic, if the effect of the intervention is mainly driven by less important components [20]. In
Table 3. Exploratory subgroup analysis on complete cases (n = 705)�.
Subgroup analysis† Number/total (percentage) Unadjusted Adjusted
Pre-intervention Intervention OR‡ (95% CI) p-Value§ OR¶ (95% CI) p-Value§
Low/intermediate-risk population (<10%)
Antibiotic prescription 29/172 (17%) 15/234 (6%) 0.37 (0.15–0.94) 0.04 0.31 (0.12–0.81) 0.02
Strategy failure 29/159 (18%) 39/218 (18%) 0.91 (0.43–1.90) 0.80 0.88 (0.42–1.87) 0.75
High-risk population (>10%)
Antibiotic prescription 75/159 (47%) 83/140 (59%) 2.04 (0.84–4.94) 0.11 2.28 (0.84–6.17) 0.09
Strategy failure 42/155 (27%) 20/136 (15%) 0.45 (0.18–1.15) 0.10 0.37 (0.14–0.99) 0.05
Bolding indicates statistical significance.
�331/597 (55%) cases were complete in the pre-intervention population, of which 172/331 (52%) were in the low or intermediate risk group (n = 91 low risk; n = 81
intermediate risk); 374/402 (93%) cases were complete in the intervention population, of which 234/374 (63%) were in the low or intermediate risk group (n = 115 low
risk; n = 119 intermediate risk).
†Interaction term intervention × risk group p< 0.01.
‡Main model: clustered by hospital, adjusted for time period.
§p-Values based on multivariable logistic regression.
¶Adjusted model: main model further adjusted for age, sex, season, ill appearance, and duration of fever.
https://doi.org/10.1371/journal.pmed.1003034.t003
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our study we found that a reduction in secondary antibiotic prescriptions was the main com-
ponent of the reduction in strategy failures in the high-risk children and in those in whom we
could not calculate the risk score (S5 Table). In low/intermediate-risk children, secondary pre-
scription slightly increased, but without increasing oxygen need or fever at day 7 (proxies for
disease severity). There was no increase in complications during the intervention phase. These
observations show that our intervention was safe, with reduced strategy failure on clinically
important outcomes.
In this trial we used a threshold of 10% to define low/intermediate- versus high-risk
patients, based on previous observed diagnostic performance [12], which appeared to be safe.
Given the relatively low observed antibiotic prescription rate in the high-risk group, a higher
threshold may also be reasonable and more specific, but may carry a risk of increasing strategy
failure. These considerations highlight the difficulty in obtaining the optimal balance between
reducing overuse of antibiotics (important from a public health perspective) and at the same
time striving for the best clinical outcomes for the individual patient [19].
Other impact studies of decision rules for infections in children that combine biomarkers
and clinical characteristics are scarce. In a previous impact study, the Feverkidstool was used
as a decision rule to guide diagnostic decisions in febrile children in a tertiary hospital. This
resulted in a more standardised diagnostic approach, but did not improve the study’s second-
ary patient outcomes, namely antibiotic treatment and hospitalisation [14]. A study of Lab-
score (a decision rule combining biomarkers) failed to prove its impact on antibiotic prescrip-
tion in infants with fever without source [23]. Two studies have been reported in non-Western
countries on the impact of decision rules on antibiotic prescription [24,25]. A bacterial pneu-
monia score reduced antibiotic prescription without increasing treatment failure [24], but
requires neutrophil testing and a chest X-ray, both of which are not recommended routinely
for the management of children with suspected lower RTIs. In Tanzania an algorithm includ-
ing clinical features, CRP, and procalcitonin (PCT) reduced antibiotic prescription from
94.9% to 11.5% and improved clinical outcomes in febrile children in primary care [25]. Most
other studies focused on the impact of single point-of-care biomarkers on antibiotic prescrip-
tion. A large study in Vietnam showed a reduction of antibiotic use after CRP testing for non-
severe acute RTIs in adults as well as in children [26]. In the European ambulatory care setting,
there is evidence that CRP testing can reduce immediate antibiotic prescription in children
when appropriate guidance is provided to the healthcare professional [27,28]. A randomised
controlled trial from Switzerland studied PCT-guided treatment, but found no effect on antibi-
otic prescription rates [29].
To our knowledge, this is the first multicentre randomised trial designed to measure the
impact of a clinical decision rule on antibiotic prescription in children with suspected lower
RTI in the ED. A major strength is that our trial studied the impact of a decision rule on usual
care. Because the trial was conducted in different settings, mostly general hospitals, we believe
our findings are generalisable to general paediatric practice. We had complete information on
the outcome antibiotic prescription, good compliance to the protocol, a high follow-up rate,
and sufficient power. The sensitivity analyses showed similar results as our primary analyses,
confirming the robustness of our findings. There are also some limitations. Logistical problems
in starting the trial in 2 hospitals resulted in a longer baseline period before rollout, potentially
affecting the power of our study (Fig 1). However, the sensitivity analysis truncating this pro-
longed baseline period gave results similar to our main analysis, so we believe our overall esti-
mates are valid. Another limitation is the amount of missing Feverkidstool variables in the
pre-intervention phase, especially CRP. This did not influence our primary analyses (as CRP
was not needed in these models), but limited the number of included patients in the subgroup
analyses, where the calculated risk of the Feverkidstool was required. This may have
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introduced some bias in the subgroup analyses. Next, not all eligible children could be
included in the trial. Doctors in the ED often are under time pressure, leaving insufficient time
or attention to recruit patients for a trial, as has been acknowledged by other paediatric ED tri-
als [5,23]. Comparison of the included and non-included children showed that severely ill chil-
dren were included more frequently. This was the same in both phases of the study, and the
rate of eligible children whose families declined participation was also stable over the study
phases. Therefore, we believe there was no selection bias introduced by a lack of allocation
concealment at the individual level. We believe that we did not miss any children with severe
infections, so our results on strategy failure and complications are generalisable.
Although we could not prove an overall reduction of antibiotic prescription, our study
implies that guiding antibiotic treatment by a decision rule based on the Feverkidstool is non-
inferior in terms of safety in non-complex cases of suspected lower RTI. Moreover, patient
outcomes may be improved by better targeting of antibiotics. Implementation of the decision
rule in clinical practice would require measuring (point-of-care) CRP, which is not routinely
done in all patients with fever and respiratory symptoms [30]. However, we recommend a low
threshold for CRP measurements and risk assessments for bacterial pneumonia in these chil-
dren, and withholding antibiotics in children with a predicted risk of�10%, provided that
careful safety-netting and good access to healthcare are in place [31]. To avoid the risk of over-
prescription in children with a predicted risk of>10%, this approach should be closely moni-
tored. Future research should focus on the safety of higher decision thresholds and on the
impact in settings with higher antibiotic prescription rates at baseline, or with a larger propor-
tion of low-risk children. Our observed 30% antibiotic prescription rate at baseline for sus-
pected lower RTIs is lower than what has been described in other European EDs, where
antibiotic prescription rates range from 52% to 78% [5,6,13,32]. Even though the populations
in many studies cannot be directly compared, a recent paper showed that after adjustment for
differences in population, large variability in antibiotic prescription remains [1]. We expect
that the effect of our intervention on antibiotic prescription may therefore be larger in settings
with a higher baseline prescription rate, or in populations with a larger proportion of low-risk
children.
A clinical decision rule for childhood pneumonia did not reduce overall antibiotic prescrip-
tion, but was non-inferior in terms of strategy failure. Exploratory analyses showed that the
intervention reduced antibiotic prescriptions in low/intermediate-risk children, and that it
reduced overall strategy failures, suggesting improved targeting of antibiotics by the decision
rule.
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